Faster and safer safety cabinet fumigation
Hydrogen peroxide system offers alternative to toxic formaldehyde fumigation of safety cabinets
An easier and faster alternative to formaldehyde fumigation, the Skanair DECOSIS is a mobile unit used directly in the lab, and connected to the safety cabinet via two tubes. It functions autonomously thanks to a control system and catalytic converter.
Because it uses hydrogen peroxide (H2O2) as a biocide, decomposition products are unproblematic, and maintenance work can subsequently be safely carried out on the decontaminated cabinet.
The unit can be used to decontaminate microbiological safety cabinets in advance of maintenance work, when changing job or location, in preparation for disposal, or in the event of breakdowns or accidents.
It can also be used to decontaminate incubators, air locks and small isolators.
The cabinet continues to run in reduced mode throughout the procedure. The trained maintenance technician enters the corresponding facility parameters at a control system display, together with the quantity of H2O2 defined on the basis of the Skanair DECOSIS validation.
The process starts at the touch of a button, and runs completely automatically: the internal ventilation unit maintains slight negative pressure and feeds H2O2 vapour through the front cover into the cabinet, continuously circulating it inside the cabinet to reach all contaminated areas. The exhaust air through the cabinet‘s HEPA filter is then fed back into the Skanair DECOSIS via the second tube to be recirculated.
The decontamination phase is followed by the flushing phase: any biocides in the exhaust air from the cabinet are removed inside the Skanair DECOSIS via a catalytic converter and a final HEPA filter. This air can then be released directly into the lab, without having to be extracted via the building exhaust air system.
You may also like
Trending Articles
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Regulatory
NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case
The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach